Eugene Marquis Center

What Eugene Marquis Center does

Centre Eugène Marquis is a comprehensive cancer treatment centre (Centre de Lutte Contre le Cancer, CLCC) located in Rennes, Brittany, France. Established in 1929 as a Fondation reconnue d'utilité publique by decree, it is the only comprehensive cancer centre serving the Brittany region and operates as part of the national UNICANCER federation of French cancer centres. The centre combines diagnosis, treatment, research, and teaching under one institutional roof, delivering medical oncology, radiotherapy, surgical oncology, nuclear medicine (PET-scan, scintigraphy, sentinel lymph node), medical imaging, and laboratory biology services to adult and paediatric cancer patients.

The underlying technology portfolio includes an on-site INSERM U1242 (COSS) research unit with approximately 100 researchers and physicians, supporting INSERM-designated LTSI signal/image processing and NuMeCan nutrition-metabolism laboratories, an INCa-designated CLIP2 early-phase clinical trial centre, a genetic sequencing platform acquired in 2024 for tumour DNA analysis in triple-negative breast and biliary tract cancers, and AI-integrated prostate MRI screening. Supporting infrastructure includes the E-HOP CNIL-authorised data warehouse, the CEM@Santé patient portal and mobile application, the CEMonBus mobile prevention unit, and the Interception personalised prevention programme. Prevention initiatives span seasonal campaigns (Mars Bleu, Octobre Rose, Dry January, Soleil de Breizh, Movember).

The business model is dual. Primary revenue is generated through reimbursement by France's national health insurance system (Sécurité sociale) for inpatient and outpatient procedures, chemotherapy, radiotherapy, nuclear medicine, and imaging. Secondary revenue derives from public donations, bequests, insurance legacies, and an annual IFI (real estate wealth tax) donation campaign, plus a solidarity fundraising platform launched April 2026, channelled into research, patient comfort, and prevention. As a nonprofit foundation, the centre is cost-recovery rather than profit-maximising and is overseen by a Director General (Pr Renaud de Crevoisier) under the broader UNICANCER national federation.

Name

Eugene Marquis Center

Legal name

Centre Eugène Marquis

Website

https://centre-eugene-marquis.fr

Company type

Private

Founded year

1929

Operating status

Operating

Headcount range

251–500 employees

Short description

Centre Eugène Marquis is a nonprofit comprehensive cancer centre (CLCC) in Rennes, France, delivering oncology diagnosis, treatment, research, and teaching to patients across the Brittany region as part of the UNICANCER national network.

Ownership category

akta.pro rank

Product category

Oncology / Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Ambulatory Health Care Services (621)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Specialty Palliative Care (e.g., oncology, CHF/COPD, dementia) (HLADAHAJ)

Keywords

• Cancer treatment services
• Medical oncology care
• Radiotherapy services
• Clinical cancer research
• Supportive oncology care

Headquarters

HQ city

Rennes

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Patient care and treatment services: As a public healthcare establishment recognised as a foundation of public utility, Centre Eugène Marquis operates under France's national health insurance system (Sécurité sociale / Assurance Maladie). Revenue is generated through reimbursement of medical procedures, hospitalisation, chemotherapy, radiotherapy, nuclear medicine, and diagnostic imaging services.
2. Donations and legacies: The centre collects donations, bequests, and insurance legacies from the public, channelling funds into research innovation, patient comfort, and prevention programmes. An IFI (Impôt sur la Fortune Immobilière) donation campaign is run annually. The centre also offers a dedicated donation portal and online fundraising (cagnotte solidaire) tool.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Centre Eugène Marquis is a comprehensive cancer treatment and research centre in Rennes, France, providing multidisciplinary cancer care from diagnosis through treatment and survivorship. Core services include medical oncology, radiotherapy, brachytherapy, surgery, nuclear medicine, medical imaging, and supportive care, complemented by clinical trials, genetic testing, and prevention programmes, all delivered through a single integrated facility combining care, research (INSERM U1242), and teaching.

Product overview

Centre Eugène Marquis is a comprehensive cancer center in Rennes, France, operating as a Fondation reconnue d'utilité publique and part of the UNICANCER network. The center provides a unified platform for cancer care combining diagnosis, treatment, and research. Core services include medical oncology, radiotherapy, surgery, nuclear medicine, and supportive care. The technology portfolio includes a patient portal (CEM@Santé) and mobile app (My CEM), supported by specialized units like the genetic sequencing platform, INSERM research laboratories (COSS U1242, LTSI, NuMeCan), and a biological resources center. Prevention programs include the Interception personalized prevention program, CEMonBus mobile unit, and the lung cancer Parcours Poumon screening pathway. The center also operates an INCa-designated early-phase clinical trial center (CLIP 2) and provides telemedicine and tele-expertise services.

Differentiator

Problem solved

Functional benefit

Brands

• CEM@Santé: Patient portal and mobile application for accessing health services
• CEMonBus
• HECTOR Bretagne

Products and services

• Cancer Diagnosis and Treatment Centre Comprehensive cancer care for adults and paediatrics, including medical oncology, surgical oncology, radiotherapy, nuclear medicine, and diagnostic imaging for all cancer types (breast, prostate, melanoma, neuro-oncology, digestive, thoracic, ENT/head and neck, sarcomas, thyroid, bladder, testicular, liver and biliary tract, neuroendocrine tumours, and hereditary cancer predispositions).
• CLIP 2 Early-Phase Clinical Trials INCa-designated early-phase clinical trial programme offering cancer patients access to experimental treatments and innovative therapies through investigator-initiated and industry-sponsored studies.
• Genetic Sequencing Platform (Plateforme de Génétique) In-house DNA sequencing service for tumour genomic profiling in triple-negative breast cancer and biliary tract cancer patients, enabling identification of specific disease markers and administration of targeted therapies.
• Interception Personalised Cancer Prevention Programme Personalised cancer prevention programme identifying individuals at high risk of cancer and providing customised prevention actions, screening, and follow-up through multidisciplinary One-Stop days, including tobacco cessation, physical activity guidance, and low-dose CT scanning.
• CEMonBus Mobile Prevention Unit Mobile health prevention and promotion unit that travels throughout Brittany to raise awareness about cancer prevention, provide information on screening, and engage with local populations on healthy behaviours.
• Telemedicine and Tele-expertise Services Remote healthcare consultation services enabling patients and healthcare professionals to conduct medical appointments and obtain specialist second opinions via digital platforms.
• Supportive Care Services (Soins de Support) Comprehensive supportive care including nutrition, psychological support, pain management, physiotherapy, lymphology, psycho-geriatric oncology, palliative care, social services, socio-aesthetics, tobacco cessation, therapeutic patient education, and home follow-up coordination.
• Medical Imaging Services Medical imaging department providing radiology, nuclear medicine (scintigraphy, PET-scan), and sentinel lymph node imaging services for cancer diagnosis, staging, and treatment monitoring.
• CEM@Santé Patient Portal and Mobile App Digital patient portal and mobile application (My CEM) available on Apple App Store and Google Play, enabling patients to manage appointments, access medical results, and communicate with their care team.

Quantifiable outcome

• 96% of colorectal cancer screenings are negative; when detected early, colorectal cancer is curable in 9 out of 10 cases.
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability2 records

Feature2 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• UNICANCERcoreStrategic or Co-development PartnerCentre Eugène Marquis is an integral member of the UNICANCER network, the French national network of cancer centres. UNICANCER coordinates clinical research, promotes best practices, and represents the network nationally and internationally.
• CHU de RennescoreStrategic or Co-development PartnerCross-access agreement between CHU de Rennes and Centre Eugène Marquis allowing authorised professionals from both institutions to consult shared patient records (Dossier Patient Informatisé) for continuity of care in joint oncology cases.
• INSERM (COSS U1242)coreStrategic or Co-development PartnerINSERM research unit U1242 (COSS) is housed within the centre and comprises approximately 100 researchers and physicians. The unit conducts fundamental and translational cancer research with cellular and molecular biology facilities on-site.
• INCa (Institut National du Cancer)coreStrategic or Co-development PartnerCentre Eugène Marquis collaborates with INCa for cancer surveillance, clinical research, and participates in the Onco Data Hub platform, France's reference oncology data platform.
• Cancer registries (Registre National des Cancers de l'Enfant, Registre des Cancers du Finistère, Registre des Cancers des Pays de la Loire, Registre des Cancers de la Manche)minorStrategic or Co-development PartnerThe centre transfers patient data to cancer registries (managed under INCa and regional health agency (ARS) oversight) for cancer surveillance and evaluation of care quality. Formal data-sharing agreements are in place.
• Etablissement Français du SangminorStrategic or Co-development PartnerPatient health data may be transmitted to the French Blood Establishment as part of its public health missions in the context of patient care.
• Haute Autorité de Santé (HAS)minorStrategic or Co-development PartnerThe centre participates in the E-satis national patient satisfaction survey programme managed by HAS, collecting and publishing patient experience data.
• Regional Health Agency (ARS Bretagne)minorStrategic or Co-development PartnerThe centre collaborates with the regional health agency for cancer registry oversight, regional health planning, and public health initiatives including prevention campaigns (Mars Bleu, Soleil de Breizh).
• HECTOR BretagneminorStrategic or Co-development PartnerHECTOR Bretagne is a professional training programme run by Centre Eugène Marquis, offering continuing education for healthcare professionals in oncology across the Brittany region.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Institut Curie: Paris-based Centre de Lutte Contre le Cancer (CLCC) and UNICANCER member operating a comprehensive cancer hospital, research centre (CNRS/INSERM units), and early-phase trial activity. Directly comparable as a French non-profit CLCC combining care, research, and teaching, although larger in scale than CEM.
• Centre Oscar Lambret: Lille-based CLCC and UNICANCER member delivering comprehensive cancer care, research, and teaching in northern France. Same French CLCC institutional model and service scope as Centre Eugène Marquis.
• Institut Bergonié: Bordeaux-based CLCC and UNICANCER member providing surgery, radiotherapy, medical oncology, and clinical research. Direct structural peer as a regional French comprehensive cancer centre with research-care integration.
• Institut Paoli-Calmettes: Marseille-based CLCC and UNICANCER member providing medical oncology, radiotherapy, surgery, and on-site research units. Same French CLCC model as CEM, serving a different regional catchment.
• Gustave Roussy: Largest French CLCC and UNICANCER member, ranked among Europe's leading comprehensive cancer centres, with full multimodal oncology, INSERM research units, and a major early-phase trial centre. Comparable mission and structure to CEM, but at significantly greater scale and with global brand recognition.
• Centre François Baclesse: Caen-based CLCC and UNICANCER member covering Normandy, with multimodal oncology, a clinical research centre, and supportive care programmes. Similar regional-comprehensive-cancer-centre positioning to CEM in Brittany.
• Centre Léon Bérard: Lyon-based CLCC and UNICANCER member delivering comprehensive cancer care, clinical research, and translational research (CRCL/INSERM). Closely comparable as a regional French comprehensive cancer centre with research-care integration similar to CEM.
• Institut de Cancérologie de l'Ouest (ICO): Western France cancer centre operating across Nantes and Angers sites, offering multimodal oncology and a research unit. Comparable as a regional French cancer centre, though operating across two sites unlike CEM's single Rennes site.
• Centre Jean Perrin: Clermont-Ferrand-based CLCC and UNICANCER member offering comprehensive cancer care and translational research, including INSERM-affiliated teams. Comparable as a mid-sized French regional CLCC similar in scale to Centre Eugène Marquis.

Broad incumbents

• CHU de Rennes: University hospital in Rennes with which Centre Eugène Marquis has a cross-access patient record agreement for joint oncology cases. Functions as a larger general hospital partner in the same city, providing inpatient and surgical capacity that complements CEM's specialist oncology focus.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Eugene_Marquis

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eugene Marquis Center